CNBG-VIROGIN BIOTECH(SHANGHAI)CO.,LTD. ("CNBG") is a Sino-foreign joint venture jointly funded by China Biotechnology Co., Ltd. and Shanghai Fu Nuojian Biotechnology Co., Ltd. The company was established in 2019. Established in May 2005, located in Nanxiang Precision Medicine Industrial Park, Jiading District, Shanghai. After the establishment of the company, the company will give full play to the advantages of China Biotech and Fonova in the fields of R&D, clinical, production, sales, etc. To achieve complementary advantages, collaborative innovation, use viral vectors as a platform, and introduce a new generation of oncolytic viruses, mRNA vaccines, and vector vaccines. And a series of products such as personalized precision diagnosis and treatment. On September 25, 2021,  CNBG-Virogin mRNA vaccine industrialization base officially started. CNBG-Virogin mRNA vaccine industrialization base is aimed at the mutation of new coronavirus The vaccine research and development and industrialization project of the strain, with a total construction area of 32513.86 square meters and a production workshop of more than 16,000 square meters. After completion and commissioning, it will become a domestically leading mRNA vaccine production workshop in terms of design capacity and technology, which fully meets the needs of biomedical automation and informatization. , Intelligent and international requirements, to create a low-carbon, energy-saving, and environmentally friendly modern intelligent mRNA vaccine industrialization base.